Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.

@article{Yang2018QuantificationOH,
  title={Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.},
  author={Hung-chih Yang and Hsiao Hui Tsou and Sung-nan Pei and Cheng-Shyong Chang and Jia-Hong Chen and Ming Yao and Sabrina Lin and Johnson Chin-Chung Lin and Quan Yuan and Ningshao Xia and Tian Zhen Liu and Pei-Jer Chen and Anthony S. K. Cheng and Christine Hsu},
  journal={Journal of hepatology},
  year={2018},
  volume={69 2},
  pages={
          286-292
        }
}
BACKGROUND & AIMS Absence or low anti-HBV surface antibody (anti-HBs) is associated with an increased risk of HBV reactivation in patients with lymphoma and resolved HBV infection receiving rituximab-containing chemotherapy. Quantification of anti-HBV core antibody (anti-HBc) is a new marker associated with the natural history and treatment response of chronic HBV infection. This study investigated whether baseline anti-HBc and anti-HBs levels may better predict HBV reactivation. METHODS We… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 37 times. VIEW TWEETS